1998
DOI: 10.1093/jac/42.6.683
|View full text |Cite
|
Sign up to set email alerts
|

Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
38
0
1

Year Published

1999
1999
2019
2019

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(42 citation statements)
references
References 0 publications
3
38
0
1
Order By: Relevance
“…The presence of horizontallyacquired genes accounted in part for elevated nalidixic acid MICs in strains that harboured these genes, but not completely. It is therefore possible that other resistance mechanisms, such as ParE polymorphisms, other horizontally acquired resistance genes, over-active efflux, or even novel mechanisms are present in some of the isolates (Martínez et al, 1998).…”
Section: Amentioning
confidence: 99%
“…The presence of horizontallyacquired genes accounted in part for elevated nalidixic acid MICs in strains that harboured these genes, but not completely. It is therefore possible that other resistance mechanisms, such as ParE polymorphisms, other horizontally acquired resistance genes, over-active efflux, or even novel mechanisms are present in some of the isolates (Martínez et al, 1998).…”
Section: Amentioning
confidence: 99%
“…So far, five qnr genes were recognized (qnr A, B, S, C and D) which encode Qnr proteins that inhibit quinolones binding to their bacterial targets (Kulková et al, 2014, Azadpour et al, 2014, Alheib et al, 2015. These qnr genes best owa low resistance level to quinolones, however, it supportsthe selection of chromosomal mutations resulting in resistance development in the host strain (Martinez et al, 1998).…”
Section: Introductionmentioning
confidence: 96%
“…High-level fluoroquinolone resistance does not develop by a single-step gyrA mutation, in contrast to nalidixic acid resistance (29,34). parC, which encodes topoisomerase IV, is also targeted by quinolone antibiotics, presumably because the QRDR of parC is highly homologous to that of gyrA.…”
mentioning
confidence: 99%